<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01725243</url>
  </required_header>
  <id_info>
    <org_study_id>12-07</org_study_id>
    <nct_id>NCT01725243</nct_id>
  </id_info>
  <brief_title>Carbetocin at Cesarean Delivery for Labor Arrest</brief_title>
  <official_title>Carbetocin at Cesarean Delivery for Labor Arrest: A Dose Finding Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Samuel Lunenfeld Research Institute, Mount Sinai Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Samuel Lunenfeld Research Institute, Mount Sinai Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In 2009, the Society of Obstetricians and Gynecologists Canada, which produces national&#xD;
      clinical guidelines on important women's health issues, recommended that a bolus of&#xD;
      carbetocin 100 mcg into your vein should be used at elective cesarean delivery instead of&#xD;
      oxytocin infusion for the prevention of bleeding after you deliver your baby. Similar to&#xD;
      oxytocin, carbetocin has side effects that are dose-related. Although 100 mcg has been the&#xD;
      recommend dose, studies in nonlaboring women suggest that doses lower than 100 mcg may be&#xD;
      used to achieve the same degree of uterine contractility with less side effects. So far, the&#xD;
      ideal dose to be used in cesarean sections for labouring women who have failure to progress&#xD;
      in labour (failure of your cervix to dilate adequately to 10cm or the baby's head not&#xD;
      descending the birth canal) has not been determined. This study is designed to determine the&#xD;
      minimum carbetocin dose required during cesarean delivery for 'failure to progress' to&#xD;
      achieve the best effect.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Post-partum hemorrhage (PPH) is a major cause of maternal death worldwide. Oxytocin is the&#xD;
      most common uterotonic drug used to prevent and treat PPH in North America, however, there&#xD;
      are some limitations to its use. Oxytocin has a very short duration of action, which requires&#xD;
      a continuous infusion to achieve sustained uterotonic activity. The Society of Obstetricians&#xD;
      and Gynecologists of Canada (SOGC) has recently recommended a single 100mcg dose of&#xD;
      carbetocin at elective Cesarean delivery to promote uterine contraction and prevent post&#xD;
      partum hemorrhage (PPH), in lieu of the more traditional oxytocin regimens. Carbetocin lasts&#xD;
      4 to 7 times longer than oxytocin, with a similar side effect profile and apparent greater&#xD;
      efficacy rate.&#xD;
&#xD;
      The evidence reported for Carbetocin use in the literature has mostly been based upon low&#xD;
      risk non-laboring patients undergoing elective cesarean deliveries. At present, only 2&#xD;
      studies have looked at the use of Carbetocin in low risk patients requiring emergency&#xD;
      cesarean deliveries. The minimum effective dose (ED90) of carbetocin in laboring women has&#xD;
      not been determined so far. Similar to oxytocin, the ED90 of Carbetocin is likely to be&#xD;
      higher in laboring women undergoing Cesarean deliveries as compared to the non-laboring&#xD;
      women, due to the effect of the desensitization phenomenon.&#xD;
&#xD;
      This study will be conducted as a prospective, randomized, up-down sequential allocation&#xD;
      trial. The success or fail of a patient in the study will determine the dose given to future&#xD;
      patients. Dosage will be increased for patients following a failed case, and kept the same&#xD;
      for patients following successful cases. Following a successful case, there is also a 1 in 9&#xD;
      chance that the dose will be decreased for the next patient.&#xD;
&#xD;
      The results of this study will establish the minimum effective dose of carbetocin for uterine&#xD;
      contraction at cesarean delivery for labor arrest. This will likely minimize unnecessary side&#xD;
      effects caused by a large bolus dose of the drug, and improve quality and safety of patient&#xD;
      care.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2012</start_date>
  <completion_date type="Actual">April 2013</completion_date>
  <primary_completion_date type="Actual">March 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>need for additional uterotonics</measure>
    <time_frame>30 minutes</time_frame>
    <description>need for additional uterotonics in the OR at the time of cesarean section based upon the assessment of unsatisfactory/indeterminate uterine tone in response to the single bolus of carbetocin.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>uterine tone</measure>
    <time_frame>10 minutes</time_frame>
    <description>Incidence of satisfactory, unsatisfactory and indeterminate uterine tone at every minute for five minutes and at 10 minutes following the completion of the injection of carbetocin.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>uterine tone</measure>
    <time_frame>2 hours</time_frame>
    <description>Incidence of satisfactory, unsatisfactory/ indeterminate uterine tone as determined by the obstetrician/nurse after trans-abdominal palpation of the uterus in PACU within 2 hours of delivery of the placenta</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>need for additional uterotonic</measure>
    <time_frame>24 hours</time_frame>
    <description>Need for delayed additional uterotonics within 24 hours after delivery outside the OR.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood loss</measure>
    <time_frame>24 hours</time_frame>
    <description>Estimated blood loss will be calculated using blood results prior to the cesarean delivery and 24 hours post-delivery.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>side effects</measure>
    <time_frame>2 hours</time_frame>
    <description>Any of the following will be noted up to 2 hours post delivery: systolic blood pressure &lt; 80% of pre-delivery values, tachycardia &gt; 30% pre-delivery levels, bradycardia &lt; 30% pre-delivery levels, other dysrhythmias, nausea, vomiting, chest pain, shortness of breath, headache, flushing, others</description>
  </secondary_outcome>
  <number_of_arms>8</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Postpartum Hemorrhage</condition>
  <arm_group>
    <arm_group_label>Carbetocin 10mcg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Carbetocin 10mcg IV, once following delivery.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Carbetocin 20mcg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Carbetocin 20mcg IV, once following delivery.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Carbetocin 40mcg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Carbetocin 40mcg IV, once following delivery.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Carbetocin 60mcg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Carbetocin 60mcg IV, once following delivery.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Carbetocin 80mcg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Carbetocin 80mcg IV, once following delivery.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Carbetocin 100mcg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Carbetocin 100mcg IV, once following delivery.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Carbetocin 120mcg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Carbetocin 120mcg IV, once following delivery.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Carbetocin 140mcg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Carbetocin 140mcg IV, once following delivery.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carbetocin</intervention_name>
    <description>Carbetocin IV, over 1 minute following delivery. Doses: 10, 20, 40, 60, 80, 100, 120 or 140mcg</description>
    <arm_group_label>Carbetocin 100mcg</arm_group_label>
    <arm_group_label>Carbetocin 10mcg</arm_group_label>
    <arm_group_label>Carbetocin 120mcg</arm_group_label>
    <arm_group_label>Carbetocin 140mcg</arm_group_label>
    <arm_group_label>Carbetocin 20mcg</arm_group_label>
    <arm_group_label>Carbetocin 40mcg</arm_group_label>
    <arm_group_label>Carbetocin 60mcg</arm_group_label>
    <arm_group_label>Carbetocin 80mcg</arm_group_label>
    <other_name>Duratocin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  All patients who have given written informed consent to participate in this study.&#xD;
&#xD;
          -  All patients planned for uncomplicated low transverse cesarean delivery secondary to&#xD;
             labor arrest, under epidural anesthesia.&#xD;
&#xD;
          -  ≥37 week pregnancy&#xD;
&#xD;
          -  Singleton pregnancy&#xD;
&#xD;
          -  Patients who have received oxytocin for at least 4 hours for labor augmentation&#xD;
&#xD;
          -  ASA 1 or 2&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Refusal or inability to obtain informed consent.&#xD;
&#xD;
          -  All patients who claim allergy or hypersensitivity to oxytocin and carbetocin.&#xD;
&#xD;
          -  Previous history of uterine atony or PPH&#xD;
&#xD;
          -  Risk factors for PPH such as pre-eclampsia, polyhydramnios, uterine fibroids, bleeding&#xD;
             diathesis and chorioamnionitis etc.&#xD;
&#xD;
          -  Abnormal placental implantation (known or suspected)&#xD;
&#xD;
          -  &gt; 3 cesarean sections in the past&#xD;
&#xD;
          -  Previous classic uterine incision&#xD;
&#xD;
          -  Macrosomia - Estimated fetal weight &gt; 4500g&#xD;
&#xD;
          -  Hemoglobin &lt; 100g/L&#xD;
&#xD;
          -  Cesarean section under general anesthesia&#xD;
&#xD;
          -  ASA 3 and 4 or patients with hepatic, renal, cardiac (eg. Coronary artery disease) and&#xD;
             vascular disease&#xD;
&#xD;
          -  Genital development problems (eg. Abnormal uterus, cervix, vagina, etc.)&#xD;
&#xD;
          -  Uncontrolled hypotension or hypertension&#xD;
&#xD;
          -  Uncontrolled diabetes&#xD;
&#xD;
          -  Abnormal heart rhythms and bradycardia&#xD;
&#xD;
          -  Drug abusers&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mrinalini Balki, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>MOUNT SINAI HOSPITAL</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mount Sinai Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G1X5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>May 2013</verification_date>
  <study_first_submitted>November 8, 2012</study_first_submitted>
  <study_first_submitted_qc>November 8, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 12, 2012</study_first_posted>
  <last_update_submitted>May 28, 2013</last_update_submitted>
  <last_update_submitted_qc>May 28, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 30, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>pregnancy</keyword>
  <keyword>postpartum hemorrhage</keyword>
  <keyword>Cesarean delivery</keyword>
  <keyword>carbetocin</keyword>
  <keyword>failure to progress in labor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Postpartum Hemorrhage</mesh_term>
    <mesh_term>Hemorrhage</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carbetocin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

